These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23392506)

  • 1. Liquid refreshment.
    Scott C
    Nat Biotechnol; 2013 Feb; 31(2):115. PubMed ID: 23392506
    [No Abstract]   [Full Text] [Related]  

  • 2. Incubators for innovators.
    Kirkpatrick L
    Nat Biotechnol; 2015 Feb; 33(2):129-32. PubMed ID: 25658271
    [No Abstract]   [Full Text] [Related]  

  • 3. First rounders podcast: Daphne Zohar.
    Nat Biotechnol; 2014 Dec; 32(12):1191. PubMed ID: 25489832
    [No Abstract]   [Full Text] [Related]  

  • 4. Beyond the crunch.
    Nat Rev Drug Discov; 2009 Jan; 8(1):3. PubMed ID: 19123266
    [No Abstract]   [Full Text] [Related]  

  • 5. The biopharmaceutical anomaly.
    Senior M
    Nat Biotechnol; 2020 Jul; 38(7):798-805. PubMed ID: 32606475
    [No Abstract]   [Full Text] [Related]  

  • 6. Taiwan biotech buoyed by colossal financings.
    Cyranoski D
    Nat Biotechnol; 2014 Jun; 32(6):508-10. PubMed ID: 24911482
    [No Abstract]   [Full Text] [Related]  

  • 7. BioXell: an Italian biotech success story?
    Sheridan C
    Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198
    [No Abstract]   [Full Text] [Related]  

  • 8. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 10. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 11. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 12. Public sector seeks to bridge 'valley of death'.
    Moran N
    Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
    [No Abstract]   [Full Text] [Related]  

  • 13. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 14. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 15. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 16. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapping into foundations.
    Nordling L
    Nat Biotechnol; 2007 May; 25(5):501-4. PubMed ID: 17571344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's fueling the biotech engine-2012 to 2013.
    Aggarwal RS
    Nat Biotechnol; 2014 Jan; 32(1):32-9. PubMed ID: 24406926
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech's wellspring--a survey of the health of the private sector in 2014.
    Huggett B
    Nat Biotechnol; 2015 May; 33(5):470-7. PubMed ID: 25965753
    [No Abstract]   [Full Text] [Related]  

  • 20. Battle over eye medicine gives drugmaker a dose of reality.
    Hayden EC
    Nat Med; 2008 Feb; 14(2):108. PubMed ID: 18256604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.